Show simple item record

dc.contributor.authorDowsett, Mitch
dc.contributor.authorTobias, J S
dc.contributor.authorHowell, Anthony
dc.contributor.authorBlackman, G M
dc.contributor.authorWelch, H
dc.contributor.authorKing, N
dc.contributor.authorPonzone, R
dc.contributor.authorVon Euler, M
dc.contributor.authorBaum, M
dc.date.accessioned2009-12-14T12:51:35Z
dc.date.available2009-12-14T12:51:35Z
dc.date.issued1999-01
dc.identifier.citationThe effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. 1999, 79 (2):311-5 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid9888474
dc.identifier.doi10.1038/sj.bjc.6690050
dc.identifier.urihttp://hdl.handle.net/10541/87858
dc.description.abstractThirty-four post-menopausal women with early breast cancer who had received 20 mg tamoxifen once daily as adjuvant therapy for at least 10 weeks participated in a randomized, double-blind, parallel-group, multicentre trial. The primary aim of the trial was to determine the effect of anastrozole upon tamoxifen pharmacokinetics, with secondary aims of assessing the tolerability of the two drugs in combination and whether or not tamoxifen had any effect upon the oestradiol suppression seen with anastrozole. Patients were randomized to receive either 1 mg anastrozole (16 patients) or matching placebo (18 patients) once daily on a double-blind basis for 28 days. No significant difference (P = 0.919) was observed in serum tamoxifen concentrations between the anastrozole and placebo groups during the trial. The serum concentration of oestradiol was significantly suppressed (P < 0.0001) in patients co-administered anastrozole compared with placebo in the presence of tamoxifen, confirming that anastrozole remained an effective suppressant of oestradiol in the presence of tamoxifen. The combination of tamoxifen and anastrozole was well tolerated, with very little difference in side-effects reported between anastrozole and placebo. In conclusion, the results of this study confirm that anastrozole does not affect the pharmacokinetics of tamoxifen when the two drugs are given in combination to post-menopausal women with early breast cancer. In addition, the oestradiol suppressant effects of anastrozole appear unaffected by tamoxifen.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogensen
dc.subject.meshAntineoplastic Agents, Hormonal
dc.subject.meshBreast Neoplasms
dc.subject.meshDouble-Blind Method
dc.subject.meshEstrogens
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshNitriles
dc.subject.meshPostmenopause
dc.subject.meshTamoxifen
dc.subject.meshTriazoles
dc.titleThe effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.en
dc.typeArticleen
dc.contributor.departmentAcademic Department of Biochemistry, Royal Marsden Hospital, London, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThirty-four post-menopausal women with early breast cancer who had received 20 mg tamoxifen once daily as adjuvant therapy for at least 10 weeks participated in a randomized, double-blind, parallel-group, multicentre trial. The primary aim of the trial was to determine the effect of anastrozole upon tamoxifen pharmacokinetics, with secondary aims of assessing the tolerability of the two drugs in combination and whether or not tamoxifen had any effect upon the oestradiol suppression seen with anastrozole. Patients were randomized to receive either 1 mg anastrozole (16 patients) or matching placebo (18 patients) once daily on a double-blind basis for 28 days. No significant difference (P = 0.919) was observed in serum tamoxifen concentrations between the anastrozole and placebo groups during the trial. The serum concentration of oestradiol was significantly suppressed (P < 0.0001) in patients co-administered anastrozole compared with placebo in the presence of tamoxifen, confirming that anastrozole remained an effective suppressant of oestradiol in the presence of tamoxifen. The combination of tamoxifen and anastrozole was well tolerated, with very little difference in side-effects reported between anastrozole and placebo. In conclusion, the results of this study confirm that anastrozole does not affect the pharmacokinetics of tamoxifen when the two drugs are given in combination to post-menopausal women with early breast cancer. In addition, the oestradiol suppressant effects of anastrozole appear unaffected by tamoxifen.


This item appears in the following Collection(s)

Show simple item record